We are pleased to invite you to the Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit, scheduled for June 5-6, 2019, in Berlin, Germany.
A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.